In practice: Anti-TNF biosimilars in rheumatic disease
Episode 4: Non-medical switching – Why, who and how?
What is non-medical switching? Dr Christopher Holroyd joins Professor Peter Taylor to discuss its potential benefits and consequences, and how to ensure suitability and provide the best support when used in people with rheumatoid arthritis.
Meet the experts
Professor Peter Taylor
Professor Peter Taylor holds the Norman Collison Chair of Musculoskeletal Sciences at the University of Oxford, UK, and is a Fellow of St Peter’s College, Oxford. He is the Director of Experimental Rheumatology at the Botnar Research Centre within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences. He is also Chief Medical Advisor to the National Rheumatoid Arthritis Society, a patient-led charity that works to support people with rheumatoid arthritis and juvenile inflammatory arthritis.
Professor Taylor has over 30 years of experience in clinical trial design and international leadership in studies of biologic and small molecular therapies in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, including the earliest seminal trails of anti-TNF and anti-interleukin-6 receptor therapy.
Disclosures
Professor Taylor has received research grants from Celgene and Galapagos, and consultation fees from AbbVie, Biogen, Fresenius Kabi, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Novartis, Pfizer, Roche, Sanofi, and UCB.
Dr Christopher Holroyd
Dr Christopher Holroyd is a Consultant Rheumatologist at University Hospital Southampton, UK, where he is the clinical lead and leads the biological therapies service. Alongside his clinical work, Dr Holroyd continues to have a keen research interest, predominantly in inflammatory arthritis. Recently, he was working group lead and first author for the BSR Biological Therapies Safety Guidelines.
Disclosures
Dr Holroyd has received speaker fees and consultancies from AbbVie, Bristol Myers Squibb, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Roche, and UCB.
Developed by EPG Health, for Medthority. This content has been developed independently of the sponsor, Sandoz, who has had no editorial input into the content. Medthority received unrestricted educational grant funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information and associated relevant content, without any promotional intent. This content is intended for healthcare professionals only.